News | Jacobio Pharma

60 press releases in total

2023

Jul 21, 2023

Jacobio Pharma to Present Data of Glecirasib in Combination with JAB-3312 at the 2023 ESMO Conference

[More]
Jul 4, 2023

Jacobio Receives CDE Approval for Glecirasib’s Pancreatic Cancer Pivotal Study in China

[More]
Jun 29, 2023

Jacobio Pharma Presents Clinical Results of Glecirasib in Colorectal Cancer

[More]
Jun 8, 2023

Jacobio Pharma Receives IND Approval for PARP7 Inhibitor JAB-26766 in China

[More]
Apr 18, 2023

Jacobio Pharma Presented Data of Three Preclinical Studies at the 2023 AACR Annual Meeting

[More]
Apr 4, 2023

Jacobio Pharma Receives IND Approval for LIF mAb JAB-BX300 in China

[More]
Mar 22, 2023

Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA® (pembrolizumab) for patients with cancer

[More]
Mar 22, 2023

Jacobio Pharma Announces 2022 Annual Results

[More]
Mar 17, 2023

Jacobio Receives IND Approval for GUE Inhibitor JAB-24114 in China

[More]
Mar 15, 2023

Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting

[More]
Jan 8, 2023

Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S.

[More]

2022

Dec 16, 2022

Jacobio’s KRAS G12C Inhibitor JAB-21822 was Granted Breakthrough Therapy Designations by China CDE

[More]
Dec 2, 2022

Jacobio’s Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022

[More]
Oct 29, 2022

Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 in China

[More]
Oct 13, 2022

Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab

[More]
Sep 16, 2022

Jacobio Completes First Patient Dosage of JAB-21822’s Phase II Pivotal Study in China

[More]
Sep 6, 2022

Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-21822’s Phase II Pivotal Study in China

[More]
Sep 2, 2022

Jacobio Completes First Patient Dosage of CD73 mAb JAB-BX102 in China

[More]
Sep 1, 2022

Jacobio Completes First Dose of IIa Clinical Trial of JAB-21822 on KRAS G12C and STK11 Co-mutation in China

[More]
Aug 23, 2022

Jacobio Announces 2022 Interim Results

[More]

Pages